PDB12 COST-MINIMIZATION ANALYSIS OF INSULIN LISPRO 50/50 VERSUS INSULIN ASPART 30/70 PREMIXED FORMULATIONS IN TYPE II DIABETES.

As healthcare spending on diabetes and its complications continues to rise, the optimization of prescribed insulin regimens is becoming increasingly important from both clinical and economic perspectives. Not only the prevalence of diabetes is high in Iran, but also the rate of diabetes complications is relatively high due to uncontrolled glucose level. Direct medical costs including pharmacy, complication, adverse events, and patient management costs were calculated in local currency Iranian Rial (IRR) and sensitivity analyses were performed. [Extracted from the article]